Literature DB >> 20180645

Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness.

Yu Kyung Cho1, Myung-Gyu Choi, Chul Hyun Lim, Kwan Woo Nam, Jae Hyuck Chang, Jae Myung Park, In Seok Lee, Sang Woo Kim, Kyu Yong Choi, In-Sik Chung.   

Abstract

OBJECTIVES: Data supporting the use of the proton pump inhibitor (PPI) test as a diagnostic test of gastroesophageal reflux disease (GERD) in Asia are lacking. The aims of this study were to evaluate the diagnostic characteristics of the PPI test and factors associated with responsiveness to PPIs.
METHODS: The PPI test was evaluated using lansoprazole (30 mg bid) for two weeks. All patients underwent endoscopy after symptom assessment. Patients without erosive esophagitis (ERD) underwent 48 h esophageal Bravo pH monitoring. Subjects were considered to be responsive to PPIs if they reported a > 50% reduction in reflux symptom score.
RESULTS: Seventy-three patients (M:F = 40:37, 47 +/- 13 years) were enrolled. We identified 46 patients with ERD, 18 patients with nonerosive reflux disease (NERD) and 9 patients without GERD. The PPI response rate was higher in patients with GERD than in patients without GERD (49/64, 77% vs. 4/9, 44%; p < 0.05). The sensitivity, specificity, and positive and negative predictive values were 77%, 56%, 92% and 25%, respectively. The PPI responsiveness was 80% (37/46) in the ERD group and 67% (12/18) in the NERD group. PPI response was not affected by age, sex, Helicobacter pylori, the psychological characteristics or cytochrome P2C genotypes. ERD and symptom-reflux association were the factors affecting PPI responsiveness.
CONCLUSIONS: The PPI test was modestly sensitive and specific for diagnosing GERD. However, it would be useful for discriminating patients with ERD. In the NERD group, patients with positive symptom-reflux association would be most benefit from PPI treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180645     DOI: 10.3109/00365521003650172

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  The value of early wireless esophageal pH monitoring in diagnosing functional heartburn in refractory gastroesophageal reflux disease.

Authors:  Eun-Young Park; Myung-Gyu Choi; Meonggi Baeg; Chul-Hyun Lim; Jinsu Kim; Yukyung Cho; Jaemyung Park; Inseok Lee; Sangwoo Kim; Kyuyong Choi
Journal:  Dig Dis Sci       Date:  2013-06-14       Impact factor: 3.199

2.  Diagnosing GORD in Respiratory Medicine.

Authors:  Chris J Timms; Deborah H Yates; Paul S Thomas
Journal:  Front Pharmacol       Date:  2011-07-22       Impact factor: 5.810

3.  Symptom characteristics and psychosomatic profiles in different spectrum of gastroesophageal reflux disease.

Authors:  Chul-Hyun Lim; Myung-Gyu Choi; Myong Ki Baeg; Sung Jin Moon; Jin Su Kim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Sang Woo Kim; Kyu Yong Choi
Journal:  Gut Liver       Date:  2013-11-05       Impact factor: 4.519

4.  Recurrence and Its Impact on the Health-related Quality of Life in Patients with Gastroesophageal Reflux Disease: A Prospective Follow-up Analysis.

Authors:  Yang Won Min; Yong Woon Shin; Gab Jin Cheon; Kyung Sik Park; Hyun Soo Kim; Chong-Il Sohn; Tae Nyeun Kim; Hyeung Cheol Moon; Poong-Lyul Rhee
Journal:  J Neurogastroenterol Motil       Date:  2016-01-31       Impact factor: 4.924

5.  Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis.

Authors:  Mengyu Zhang; John E Pandolfino; Xuyu Zhou; Niandi Tan; Yuwen Li; Minhu Chen; Yinglian Xiao
Journal:  Therap Adv Gastroenterol       Date:  2019-11-21       Impact factor: 4.409

6.  The Diagnostic Significance of Coapplying a Rabeprazole Test with the SF-36 for Gastroesophageal Reflux Disease.

Authors:  Ying Chen; Feng Wang; Yuanxi Jiang; Chen Wang; Liwen Yao; Ping Wu; Yili Tong; Huihui Sun; Shuchang Xu
Journal:  Gastroenterol Res Pract       Date:  2013-02-28       Impact factor: 2.260

7.  Factors influencing treatment outcome in patients with gastroesophageal reflux disease: outcome of a prospective pragmatic trial in Asian patients.

Authors:  Khean Lee Goh; Kee Don Choi; Myung-Gyu Choi; Tsai-Yuan Hsieh; Hwoon-Yong Jung; Han-Chung Lien; Jayaram Menon; Steven Mesenas; Hyojin Park; Bor-Shyang Sheu; Justin Cy Wu
Journal:  BMC Gastroenterol       Date:  2014-09-09       Impact factor: 3.067

Review 8.  Pharmacological and Safety Profile of Dexlansoprazole: A New Proton Pump Inhibitor - Implications for Treatment of Gastroesophageal Reflux Disease in the Asia Pacific Region.

Authors:  Khean Lee Goh; Myung Gyu Choi; Ping I Hsu; Hoon Jai Chun; Varocha Mahachai; Udom Kachintorn; Somchai Leelakusolvong; Nayoung Kim; Abdul Aziz Rani; Benjamin C Y Wong; Justin Wu; Cheng Tang Chiu; Vikram Shetty; Joseph C Bocobo; Melchor M Chan; Jaw-Town Lin
Journal:  J Neurogastroenterol Motil       Date:  2016-07-30       Impact factor: 4.924

9.  Validation of the Korean Version of the Gastroesophageal Reflux Disease Questionnaire for the Diagnosis of Gastroesophageal Reflux Disease.

Authors:  Eun Jeong Gong; Kee Wook Jung; Yang-Won Min; Kyoung Sup Hong; Hye-Kyung Jung; Hee Jung Son; Do Yeon Kim; Jungbok Lee; Oh Young Lee
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.